---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-071512"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:28:51.068960+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Celldex shareholders approve 3.2M share increase to equity plan; director award limits raised

## Summary
- Stockholders approved amendment increasing share reserve from 4.3M to 7.5M shares under 2021 Omnibus Plan.
- Non-employee director annual award limit raised to $750K ($1.2M for new directors) effective after stockholder approval.
- All eight director nominees elected, including CEO Anthony Marucci and Chair Karen Shoos, with over 54.6M votes for each.
- Advisory say-on-pay vote approved with 54.2M for, 0.9M against; auditor ratification passed with 57.8M for.

## SEC filing metadata
- accession: 0001104659-24-071512
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000110465924071512/0001104659-24-071512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000110465924071512/tm2417134d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-071512
- JSON: https://secwatch.observer/filing/0001104659-24-071512.json
- Plain text: https://secwatch.observer/filing/0001104659-24-071512.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.